Latest News

eye on pharma graphic
Eye on Pharma: Bevacizumab Update; Samsung Bioepis, J&J Settlement; Another EU Trastuzumab

December 6th 2023

Outlook Therapeutics provides an update on the development of its bevacizumab candidate for age-related macular degeneration; Samsung Bioepis settles with Johnson & Johnson (J&J) over its ustekinumab biosimilar candidate; and the European Union gains another trastuzumab biosimilar.

doctor supporting patient
Study Documents HCPs’ Experiences of a Mandatory Switch to Inform Future Transitions

December 2nd 2023

HHS on a phone | Image credit: Timon - stock.adobe.com
HHS Praises Biosimilars Savings but Opportunities to Reduce Part B Spending Remain

November 28th 2023

eye on pharma banner
Eye on Pharma: Adalimumab Updates; New Eylea Biosimilar Lawsuit; Canada Gains Stelara Biosimilar

November 22nd 2023

Poland flag | Image credit: Maxim - stock.adobe.com
Public Payer in Poland Saves €243 Million by Using Biosimilar TNF Inhibitors

November 11th 2023

Video Series
Video Interviews
CFB podcast banner
cfb podcast banner
CfB podcast banner
CfB podcast banner
CfB podcast banner
"When Choice Arrives: Competition & Consequences" written over a bright blue syringe with the AJMC/The Center for Biosimilars logo in the bottom right corner
podcast banner
CfB podcast banner
CfB podcast banner
Latest CME Events & Activities

More News

© 2023 MJH Life Sciences

All rights reserved.